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Abstract
Background: S100B is a dimeric protein that can form tetramers, hexamers and higher order oligomers. These forms have
been suggested to play a role in RAGE activation.
Methodology/Principal Findings: Oligomerization was found to require a low molecular weight trigger/cofactor and could
not be detected for highly pure dimer, irrespective of handling. Imidazol was identified as a substance that can serve this
role. Oligomerization is dependent on both the imidazol concentration and pH, with optima around 90 mM imidazol and
pH 7, respectively. No oligomerization was observed above pH 8, thus the protonated form of imidazol is the active species
in promoting assembly of dimers to higher species. However, disulfide bonds are not involved and the process is
independent of redox potential. The process was also found to be independent of whether Ca
2+ is bound to the protein or
not. Tetramers that are purified from dimers and imidazol by gel filtration are kinetically stable, but dissociate into dimers
upon heating. Dimers do not revert to tetramer and higher oligomer unless imidazol is again added. Both tetramers and
hexamers bind the target peptide from p53 with retained stoichiometry of one peptide per S100B monomer, and with high
affinity (lgK=7.360.2 and 7.260.2, respectively in 10 mM BisTris, 5 mM CaCl2, pH 7.0), which is less than one order of
magnitude reduced compared to dimer under the same buffer conditions.
Conclusion/Significance: S100B oligomerization requires protonated imidazol as a trigger/cofactor. Oligomers are
kinetically stable after imidazol is removed but revert back to dimer if heated. The results underscore the importance of
kinetic versus thermodynamic control of S100B protein aggregation.
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Introduction
S100B belongs to the S100 family of small calcium-binding
proteins within the calmodulin superfamily of EF-hand proteins.
Over 20 different S100 proteins are known and all members of this
family contain two helix-loop-helix calcium-binding motifs. Most
S100 proteins are known to form a homodimer, or a heterodimer
with another S100 member, and interact with a wide range of
proteins involved mainly in the cytoskeleton and cell proliferation.
Many S100 proteins have strong medical implications in, for
example, inflammatory response, rheumatoid arthritis, cancer,
and neurological conditions. For extensive reviews, see [1-5]. The
name S100 refers to the fact that these proteins are soluble in
100% saturated ammonium sulphate solution.
S100B is found in vertebrates only and has regulatory activities
both as an intracellular and an extracellular protein. S100B is
abundant within the central nervous system, for example in glia [6].
In cells, S100B is involved in signal transduction because it inhibits
protein phosphorylation, regulates enzyme activities and is involved
in Ca
2+ homeostasis. S100B interacts with cytoskeletal proteins and
is involved in the regulation of cellular morphology. Extracellularly,
S100B is present in for example serum and spinal fluid. Here the
protein seems to act as a beneficial factor when present at low (nM)
concentration and stimulates neurite outgrowth and cell survival
through interactions with the receptor of advanced glycation end
products, the RAGE receptor [7,8]. S100B seems to both stimulate
myoblast proliferation and inhibit myoblast differentiation [9].
Under certain conditions, e.g. after cardiac surgery, cardiac arrest,
stroke, or head injury, S100B leakage into the extracellular fluids
increases to toxic levels [10]. It seems like in this situation, the
interaction with RAGE underlies the toxic effects of S100B [7]. The
concentration of S100B is used in diagnostics to predict the severity
of brain damage, e.g. after cardiac surgery [4,11].
S100B levels are elevated in the brains of patients with
Alzheimer’s disease [12] or Down’s syndrome, and the protein is
implicated in cancer. In Alzheimer’s disease the pattern of S100B
overexpression correlates with the pattern of neuritic-plaque
formation. Increased amounts of S100B are also detected in
tumours, e.g. in malignant melanoma [13] and the S100B
concentration correlates with the severity of the disease. S100B
binds to p53 and inhibits the calcium-dependent phosphorylation
of p53 by protein kinase C. This may reduce the tumour
suppressor function of p53, resulting in uncontrolled tumour
growth. S100B has also been found to affect gene expression
through interactions with transcription factors [14]. The p53
transcriptional activity is inhibited by S100B, and down-regulation
of S100B is a means to restore p53 levels [15,16].
S100B is a calcium-sensor protein, and upon Ca
2+ binding it
exposes hydrophobic surfaces that interact with target proteins
[17-20]. S100B binds two Ca
2+ ions per monomer (10.7 kDa), and
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2+ affinities are altered in the presence of the target [21]. S100B
is also a high-affinity Zn
2+-binding protein [22]. Three-dimen-
sional structures of S100B are reported for the calcium free [23]
and calcium bound [24-26] states, with both calcium and zinc
bound [27], as well as in complex with a range of peptides from
target proteins [28-30]. All these structures display S100B as a
homodimeric protein (21.5 kDa) and the affinity is so high, with
KD in the picomolar range or lower [31] that monomers are
absent under all relevant biological circumstances. S100B homo-
dimerization occurs mainly via the terminal helices, and the dimer
is not 3D-domain swapped, in contrast to the dimer found for
S100G (calbindin D9k) [32]. S100G is the only S100 protein that is
observed as a monomeric protein under physiological conditions.
The high resolution structure of a S100B octamer has recently
been reported and tetramers were proposed to trigger RAGE
activation by receptor dimerization. [33]. Here we describe the
independent discovery of S100B tetramers, hexamers and higher
order oligomers. Using highly purified dimers in the absence and
presence of potential catalyzing agents, we have determined the
conditions dictating their formation and disassembly. We show
that conversion from dimer to higher oligomers requires a low
molecular weight trigger, and that protonated imidazol can serve
as this trigger. In addition we quantify the p53 target binding
properties of tetramers and hexamers in comparison with dimer.
Results
S100B oligomerization requires a trigger
S100B tetramers and higher order oligomers were discovered by
serendipity during our initial purification of recombinant rat
S100B from E coli using heat treatment, ion exchange and size
exclusion chromatography (see File S1). The formation of S100B
tetramers and higher oligomers could be due to the very high
concentration of S100B and/or lyophilization of the protein
during purification. Alternatively, the formation of tetramers could
be due to a trigger, which could be an E coli protein or some other
substance from E coli, or any of the buffer chemicals and salts
(imidazol, EDTA, NaCl, ammonium acetate) used during
purification. To distinguish between these possibilities, the
purification protocol was expanded with hydrophobic interaction
chromatography on phenyl sepharose column between the ion
exchange and gel filtration steps. After the gel filtration S100B was
repeatedly denatured by urea and washed and desalted on a size
exclusion filter (cutoff 5 kDa) until no contaminating proteins or
small molecules could be detected by gel electrophoresis or NMR
spectroscopy. This highly purified (trigger-free) S100B dimer was
desalted and lyophylized. A fraction of the lyophylized material
was dissolved at 20 mg/ml and split in 24 samples that were
supplemented with excess Ca
2+ or EDTA, with NaCl ranging
from no added salt to saturated solution, and with pH adjusted to
5, 6, 7, 8 or 9. The samples were lyophilized and dissolved, and
then incubated for 24 hours at 4 uC followed by analytical gel
filtration on a Superdex 200 column. Only the dimer peak was
observed at all these conditions, ruling out lyophilization as the
cause of formation of S100B tetramers and higher oligomers.
Neither did we observe any higher Mw species than dimer after
concentration of the samples on spin concentrators. This batch of
highly pure S100B dimer is hereafter referred to as trigger-free
S100B.
These results show that the oligomerization of S100B dimer
requires a trigger and is not caused by high concentration of the
protein alone. Lyophilization or other means of concentration of
trigger-free S100B dimer does not yield any other species than
dimer.
Localization of the trigger along the purification protocol
The next step was to isolate and identify the trigger that lead to
the formation of S100B tetramers and oligomers. The S100B
eluate from the ion exchange column in the purification protocol
was divided into six pools that were separately lyophilized. Each
pool was dissolved in the smallest possible volume, incubated at 4
uC for 24 hours and analyzed by analytical gel filtration. The
largest amount of tetramer and higher oligomer was obtained from
pool six, representing the high salt end of the S100B eluate,
implying that the trigger was most abundant in this pool. To
further isolate the trigger, pool six was purified by hydrophobic
interaction chromatography on a phenyl sepharose column
(binding and washing in Ca
2+, elution with EDTA). One hundred
fractions were collected from the phenyl sepharose flow through,
wash and elution, and analyzed by agarose gel electrophoresis.
S100B was present in the EDTA eluate but not in the flow-
through or wash fractions. Analytical gel filtration showed that the
protein was present as a dimer in the EDTA eluate. Fractions from
the EDTA eluate were lyophilized, dissolved, incubated for 24 h
and analysed by analytical gel filtration, but no tetramer or higher
oligomer was obtained from any of these fractions. Therefore,
trigger-free S100B dimer was mixed with aliquots from flow-
through and wash fractions, lyophilized, dissolved, incubated for
24 h and analysed by gel filtration. Tetramers and higher
oligomers were obtained when trigger-free S100B was mixed with
the flow through fractions, but not the wash fractions, and there
was a clear maximum of potency to trigger S100B oligomerization
in fraction 33 representing the late flow through of the phenyl
sepharose column.
The trigger was isolated in fraction 33 and remained to be
identified.
High or low Mw trigger?
The trigger could be another protein, DNA or biological
macromolecule present in E. coli, or a low Mw substance from E.
coli or an added chemical or buffers. Phenyl sepharose fraction 33
was therefore fractionated using a 5 kDa Mw cutoff filter. The
concentrate (high molecular weight species, Mw.5 kDa) and
filtrate (low molecular weight substances, Mw,5 kDa) were
lyophilized separately with trigger-free S100B dimer, dissolved,
incubated for 24 h and analysed by analytical gel filtration as
above. S100B oligomers were obtained when the protein was
incubated with the filtrate, but not the concentrate, implying that
the trigger is a low Mw substance (,5 kDa).
We found that the trigger is a low Mw substance.
Identification of the trigger
The concentrate and filtrate from phenyl sepharose fraction 33,
as well as aliquots of all fractions from the ion exchange and
phenyl sepharose columns, were lyophylized and analyzed by
1H
NMR in D2O and in CDCl3. A large number of substances were
seen in all fractions. The only NMR signals obtained in D2O,
which correlated with the oligomerization propensity were the
characteristic intense signals from EDTA and imidazol. The only
NMR signals obtained in CDCl3, which correlated with the
oligomerization propensity were a sharp singlet at 1.26 ppm and a
much smaller signal at 0.88 ppm, features typical for very long
chain alkanes, alcohols and fatty acids (SBDS http://www.aist.go.
jp/RIODB/SDBS/menu-e.html). EDTA, imidazol and a number
of alkanes, alcohols and fatty acids with different chain lengths
were therefore evaluated in triggering experiments where they
were added alone and in different combinations to trigger-free
S100B dimer at pH 7.0 with or without NaCl up to saturating
concentration. Imidazol was identified as the substance that
S100B Oligomers
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imidazol yielded any oligomeric species higher than dimer.
Imidazol was identified as the trigger substance that promotes
formation of S100B tetramer and higher oligomers.
Tetramers contain no bound trigger
We next asked whether imidazol acts as a catalyst or whether
tetramers and oligomers are stabilized by bound imidazol.
Trigger-free S100B dimer was used in triggering experiments
with imidazol (20 mg/ml S100B, 90 mM imidazol, 1 mM EDTA,
1 mM DTT, pH 7.0). The higher oligomer, hexamer, tetramer
and dimer fractions were collected separately from the superdex
200 column, lyophilized, dissolved in D2O and subjected to NMR
spectroscopy in comparison with imidazol. As shown in Figure 2,
no imidazol signals were observed in the dimer or tetramer
fractions collected from the gel filtration column. Neither was
there any imidazol in the collected hexamers or higher oligomer
fractions (data not shown). Our data show that the tetramers and
higher oligomers are free from imidazol, hence they are not
stabilized by bound imidazol.
We found that imidazol acts as a catalyst that promotes the
formation of tetramer and higher oligomer, but once formed these
do not require imidazol to persist.
Role of pH and imidazol concentration
The role of imidazol concentration was investigated in
triggering experiments with 20 mg/ml trigger-free S100B dimer,
1 mM EDTA, 1 mM DTT, 0.25 M NaCl, pH 7 and none or 20–
900 mM imidazol. Figure 1 shows examples of chromatograms for
zero, 20 and 90 mM imidazol at pH 7. Clearly, the amount of
tetramer formed is dependent on the imidazol concentration, as
presented in more detail in Figure 3A. The role of pH investigated
in triggering experiments with 20 mg/ml trigger-free S100B dimer
in 90 mM imidazol, 1 mM EDTA, 1 mM DTT, 0.25 M NaCl at
different pH values ranging from 4 to 9. There is a clear
dependence on pH (Figure 3B), with an optimum found at pH 7
which coincides with the pKa value of imidazol. Tetramerization
is eliminated at pH values above 8 where imidazol is unprotonated
and has no charge. Replacement of imidazol with Tris buffer did
not yield any tetramers or higher oligomers (not shown).
The amount of tetramer formed is dependent on the imidazol
concentration with an optimum around 90 mM and on the pH of
the solution with an optimum around pH 7.
Role of NaCl, redox potential, Ca
2+ and Zn
2+
The role of NaCl concentrations was investigated in triggering
experiments with 20 mg/ml trigger-free S100B dimer, 1 mM
EDTA,1 mMDTT,90 mMimidazol,pH 7andnoneor10 mM–
Figure 1. Identification of the trigger. Highly pure S100B dimer
was mixed with potential triggers and lyophilized, dissolved, incubated
for 24 h at 4 uC, and analyzed by analytical gel filtration on a Superdex
200 column at room temperature. The chromatograms shown are for
samples with 20 mg/ml S100B, 1 mM EDTA, 1 mM DTT, 0.25 M NaCl, pH
7.0, and no (top), 20 mM (middle) or 90 mM imidazol .
doi:10.1371/journal.pone.0014768.g001
Figure 2. NMR spectra reveal no imidazol in S100B tetramer or
dimer isolated by gel filtration.
1H NMR spectra in D2O for imidazol
and the dimer and tetramer fractions as purified by gel filtration after
triggering of 20 mg/ml S100B with 90 mM imidazol in1 mM EDTA,
1 mM DTT and 0.25 M NaCl.
doi:10.1371/journal.pone.0014768.g002
S100B Oligomers
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not shown). The role of Ca
2+ concentrations was investigated in
triggering experiments with 20 mg/ml trigger-free S100B dimer,
90 mM imidazol, 1 mM DTT, 0.25 M NaCl, pH 7 and 1–10 mM
CaCl2 or1–10 mMEDTA.Noeffectofthe Ca
2+concentrationwas
seen (datanot shown).Theeffecyofredoxpotentialwasinvestigated
in triggering experiments with 20 mg/ml trigger-free S100B dimer,
1 mM EDTA, 90 mM imidazol, pH 7 and either 1 or 10 mM
DTT or 10 mM gluthathione at different ratios of reduced and
oxidized species. No effect of the redox potential was seen (data not
shown), hence disulfide bond formation is not involved in the
oligomerization process. Imidazol is a zinc chelator, and the effect
of zinc was therefore investigated by preparing samples of
trigger-free S100B dimer at pH 7.0 with 1 mM DTT and
0.25 M NaCl, and different combinations of Zn
2+ and imidazol.
Each sample was lyophylized, dissolved, incubated for 24 h
and analysed by analytical gel filtration. Zn
2+ was found to casue
no extra effect compared to the same imidazol concentration
without Zn
2+.
None of the factors examined governed the amount of tetramer
or higher oligomer formed.
Comparison of imidazol to related substances
The role of imidazol in comparison to the related substances
histidine, methylimidazol and poly-histidine was investigated in
triggering experiments with trigger-free S100B dimer in 1 mM
EDTA, 1 mM DTT, 0.25 M NaCl, pH 7.0 with (0–100 mM)
imidazol, 50, 100, 200, 400, or 800 mM histidine, 50, 100, 200,
400, or 800 mM methylimidazol or 0.1, 0.2, 0.4, 0.8 or 1.6 mM
poly-histidine of mean chain length 100 residues. Imidazol was the
only substance found to cause the formation of tetramer and
higher oligomer, while only dimer was observed when S100B was
incubated with histidine, methylimidazol or poly-histidine (data
not shown).
The triggering effect of imidazol was not seen with related
substances.
S100B tetramers are kinetically stable
Trigger-free S100B dimer was used in triggering experiments
with imidazol (20 mg/ml S100B, 90 mM imidazol, 1 mM EDTA,
1 mM DTT, pH 7.0). The hexamer, tetramer and dimer fractions
were collected separately from the superdex 200 column and an
aliquot of each fraction reinjected on the column (Figure 4). The
fractions stored for up to 6 months during which time aliquots
were repeatedly analyzed by analytical gel filtration on the
superdex 200 column. The tetramers were found persist for six
months in solution at 4 uC (longer times not tested). The hexamer
showed faster conversion back to dimer with approximately 50%
lost after three months of storage at 4 uC. The dimer remained
dimeric for the entire period. The time-dependent behavior was
repeated twice using different batches of oligomer, and the same
result was found. Aliquots of the newly collected tetramer and
hexamer fractions were also heated for 15 minutes at 90 uC prior
to analytical gel filtration. The heating procedure was found to
dissociate tetramers and hexamers into dimers (Figure 4). Aliquots
of the heated samples were then incubated at 4 uC for up to 7 days
and again subjected to gel filtration; however neither tetramers nor
higher oligomers were regained (not shown). The heating
experiments were repeated five times on different batches and
dissociation into dimer was seen in all cases. We also found that
the tetramers and hexamers as isolated by gel filtration cannot be
lyophilized to increase their concentration because this procedure
causes a significant amount of the protein to revert to dimer.
However, the collected multimers can be concentrated in spin
concentrators without causing any dissociation into dimers (data
not shown).
We found that the S100B tetramers are kinetically stable over
several months, but revert to dimer after thermal denaturation.
Dynamic light scattering
Trigger-free S100B dimer was used in triggering experiments
with imidazol (20 mg/ml S100B, 90 mM imidazol, 1 mM EDTA,
1 mM DTT, pH 7.0). The hexamer, tetramer and dimer fractions
were collected separately from the superdex 200 column and an
aliquot of each fraction subjected to size determination by
dynamic light scattering (Figure 5). For the dimer fraction we
observe one peak with mean radius of 2.28 nm, which for a
globular protein corresponds to a Mw of 22 kDa (21.49 expected
for S100B dimer). For the tetramer fraction we observe one peak
with mean radius of 3.10 nm, which for a globular protein would
correspond to a Mw of 47.5 kDa (43.0 expected for S100B
tetramer). The slightly higher Mw compared to the one expected
may be due to some contamination with hexamer or may reflect
that the shape is not perfectly globular. For the hexamer fraction
we observe two peaks. The major peak (94% of the intensity)
occurs at mean radius 3.66 nm, which for a globular protein
Figure 3. Tetramer formation - dependence on imidazol concentration and pH. Analytical gel filtration on a Superdex 200 column was
used to estimate the fraction of S100B in tetrameric state after triggering experiments starting with 20 mg/ml highly pure S100B dimer in 1 mM
EDTA, 1 mM DTT and 0.25 M NaCl with different concentrations of imidazol at pH 7.0 (A) or with 90 mM imidazol at different pH values (B).
doi:10.1371/journal.pone.0014768.g003
S100B Oligomers
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hexamer). Again, the slightly higher Mw compared to the one
expected may be due to some contamination with higher
oligomeric species or that the shape is not perfectly globular.
The second peak (6 % of the intensity) occurs at very large radius
and may represent further aggregation of a small fraction of the
protein.
S100B oligomers bind p53 target peptide with high
affinity
We next asked if the S100B oligomers retain their binding
affinity and stoichiometry for target peptides that are known to
interact with high affinity with the S100B dimer. Fluorescence
spectroscopy was used to measure the affinity and stoichiometry of
binding between S100B oligomers and the target peptide from
p53. The peptide used contains residues 367–388 of p53 with
phenylalanine 385 changed to a tryptophan to enable the
fluorescence studies [19]. The fluorescence emission intensity at
330 nm was monitored during stepwise addition of S100B dimer,
tertramer or hexamer stock solution. The fluorescence intensity
was plotted versus S100B concentration and a 1:1 binding model
was fitted to the data, as illustrated in Figure 6. The data show that
all three forms of S100B bind one p53 peptide per S100B
monomer, i.e. two peptides per dimer, four peptides per tetramer
and six peptides per hexamer. The peptide-binding affinity is
similar in all three cases, with
10log K values of 8.260.3 for dimer,
7.360.2 for tetramer, and 7.260.2 for hexamer.
We find that p53 binding is largely unaffected (one order of
magnitude only) by the association of S100B dimers into tetramers
and higher oligomers.
Discussion
S100B has been known for long time to form a high affinity
homodimer. Here we have reported the discovery of S100B
tetramers and higher oligomers, which were found independently
by Ostendorp et al. [33]. Using a combination of classical protein
chemistry and NMR spectroscopy and highly pure S100B dimer
we show that the conversion of S100B dimer into tetramer and
higher oligomers requires a low Mw trigger. Imidazol was
identified as a molecule that can serve as the trigger, with a pH
optimum at pH 7 which coincides with the pKa value of imidazol.
The pH dependence data clearly show that imidazol is effective
as a trigger in its protonated (positively charged) state, because the
activity is lost at pH values above 8 where imidazol in uncharged.
The more modest loss of triggering activity observed as pH is
lowered between 7 and 4.5 is most likely due to protonation of
ionizable groups in the S100B protein. The failure of other buffers
with pKa values in the same range as imidazol to trigger the
oligomerization suggests a specific role for imidazol. When isolated
by gel filtration, both tetramers and higher oligomers are found to
be free of imidazol, hence they are not stabilized by binding the
trigger. The absence of bound imidazol in the purified tetramers
and hexamers shows that imidazol facilitates the assembly of
tetramers and higher oligomers; however imidazol is not essential
for maintaining these structures once formed. The oligomers are
kinetically stable towards dissociation into dimers, with tetramers
being the most stable form. However, if the purified tetramers or
hexamers are denatured by heat and then cooled, they revert to
dimer, which agrees with the observation by NMR spectroscopy
that the triggering imidazol is not present in these species.
Figure 4. Kinetic stability. An imidazol-triggered sample of S100B
was separated into hexamer, tetramer and dimer by gel filtration and
the fractions reinjected on the Superdex 200 analytical gel filtration
column before (top two chromatograms) and after (bottom two
chromatograms) heating to 90 uC for 15 minutes.
doi:10.1371/journal.pone.0014768.g004
Figure 5. Dynamic light scattering. An imidazol-triggered sample of S100B was separated into hexamer (dotted line), tetramer (dashed line) and
dimer (solid line) by gel filtration and the fractions analyzed by dynamic light scattering.
doi:10.1371/journal.pone.0014768.g005
S100B Oligomers
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when poly-His-tags are used for purification purposes it is common
to use high concentration of imidazol in protein elution steps. The
present findings suggest that the His-tag may not be the only cause
of unexpected effects in such protein preparations, but also
imidazol may contribute. As shown in the present work, the
protein alterations caused by imidazol may persist after imidazol is
removed. For example, it was recently found that imidazol
significantly accelerates the rate of ground state recovery of the
flavin chromophore the BLUF domain of the protein AppA [34],
but in contrast to S100B tetramerization, the unprotonated form
of imidazol was found to be the active species in that case.
The higher affinity binding to RAGE of S100B tetramers
compared to S100B dimers, was inferred to couple to RAGE
dimerisation, hence allosteric couplings may explain the higher
affinity in that case [33]. All substances tested here besides imidazol
fail to induce the formation of tetramers or higher oligomers. This
includes even the related substances histidine, methyl-imidazol and
polyhistidine. Thus it remains to be found what causes the
formation of tetramers in vivo, if there is another low molecular
weight trigger or whether interaction with targets like for example
the RAGE receptor is involved. The higher affinity of RAGE for
S100B tetramer compared to dimer, implies through thermody-
namic linkage that the dimer to tetramer equilibrium constant is
higher in the presence of RAGE. Here we find that binding of the
target peptide from the tumour suppressor protein p53 is largely
retained in tetramers and hexamers, both as regards the affinity and
stoichiometry. The effect on affinity is less than an order of
magnitude and there is one p53 peptide bound per S100B
monomer both in dimer, hexamer and tetramer. This implies that
the tetramers and hexamers are functional and that the target-
binding sites are largely unperturbed in these structures.
Materials and Methods
Protein Expression
The plasmid with the rat S100B gene (kind gift from D. Weber)
was transformed in Eschericia coli BL21 De3 PLysS star and grown
in LB medium with 50 mg/l ampicillin and 30 mg/l chloram-
phenicol. 5 ml of an overnight culture was used to inoculate a
500 ml day culture in a 2.5 l baffled flask in a shaker incubator at
37 uC. IPTG was added at OD600=0.6, and the cells were
collected 3–4 hours later by centrifugation at 6000 g for 5 minutes,
and frozen.
Purification of highly pure S100B dimer
The cell pellet is sonicated on ice in buffer A (10 mM imidazol,
1 mM EDTA, pH 7.0; 40 ml buffer to pellet from 500 ml
culture) and centrifuged at 27000 g for 10 minutes. The
supernatant is poured into an equal volume of boiling buffer A,
heated to 80 uC and cooled on ice. Precipitated E. coli proteins
are removed by centrifugation at 15000 g for 10 minutes, and the
supernatant is pumped onto a DEAE cellulose column in buffer
A, washed with buffer A and eluted with a linear salt gradient
from 0 to 300 mM NaCl in buffer A. The eluted fractions are
analysed by agarose gel electrophoresis and the S100B-containing
fractions are pooled, supplemented with 2 mM CaCl2 and
300 mM NaCl and pumped onto a phenyl sepharose column
packed in buffer B (10 mM Tris, 1 mM CaCl2, 300 mM NaCl,
pH 7.5). The column is washed with buffer B and S100B dimer is
eluted with 10 mM Tris, 1 mM EDTA, 300 mM NaCl, pH 7.5.
The eluate is freeze dried and dissolved in the smallest possible
volume before gel filtration on a 3.46200 cm Sephadex G50
superfine column with 50 mM ammonium acetate, pH 6.5 as the
running buffer. Fractions containing dimeric S100B are pooled
and lyophilized. The protein is then dissolved in 8M urea with
10 mM EDTA, pH 8.0, and incubated for 2 hours to release any
small molecule inclusions. The protein is washed on a spin
concentrator (Mw cutoff 5 kDa), first with 8M urea, then with
H2O, and lyophylized. This denaturation and washing procedure
is repeated until no contaminating species could be detected by
gel electrophoresis or NMR spectroscopy and no tetramer or
higher oligomer is obtained after lyophilization. The sample is
then considered free from triggering molecules from E. coli and
can be used in oligomerization experiments under controlled
conditions.
P53 peptide expression and purification
A peptide based on the C-terminal regulatory domain of p53
with the sequence MSHLKSKKGQSTSRHKKLMWKTE (Met
followed by residues 367–388 of p53, with Phe 385 changed to
Trp), was cloned in the vector pTXb1 from New England Biolabs.
Overlapping oligonucleotides representing the forward and
reverse strands with the required overhangs were heated to 95
uC and annealed by slow cooling (2 uC per minute) to 60 uC, then
rapidly cooled to 4 uC. The product was ligated with pTXb1
vector that had been cut with Nde1 and SapI restriction enzymes,
transformed in E. coli ER2566, and spread on LB plates with 100
mg ampicillin per ml. DNA sequencing was performed on plasmids
prepared from single colonies. A plasmid with confirmed sequence
was then transformed into E. coli ER2566 and the peptide was
expressed in fusion peptide with an intein and a chitin-binding
domain. The fusion product was purified by sonication, ion
exchange on a DEAE cellulose resin in 10 mM Tris/HCl, 1 mM
EDTA, pH 7.5, using step elution with the same buffer
complemented with 0.5 M NaCl, then binding to and washing
on a chitin column in 10 mM Tris/HCl, 0.5 M NaCl, 1 mM
EDTA, pH 7.5. The peptide was cleaved off from the intein using
the same buffer supplemented with 50 mM DTT. The peptide
was then further purified by gel filtration on a G25 column,
desalted and lyophilized.
Figure 6. p53 binding. Titration of 0.9 mM p53 peptide with S100B
dimer (O), tetramer (N), or hexamer (m), together with fitted lines. The
fluorescence intensity recorded during each titration has been
normalized.
doi:10.1371/journal.pone.0014768.g006
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All buffers and purification chemicals were of analytical grade.
The following potential triggers were purchased from Sigma-
Adrich: alkanes ranging from tetradecane (C14H30) to octatria-
contane (C38H78), alcohols ranging from tetradecanol (C14H30O)
to octacosanol (C28H58O), fatty acids from tetradecanoic acid
(C14H28O2) to octacosanoic acid (C28H56O2).
Triggering experiments
Highly pure S100B dimer was used in all triggering experi-
ments. The protein solution was supplemented with a range of
different pure substances (NaCl, EDTA, imidazol, Tris, histidine,
methylimidazol, poly-L-histidine, alkanes ranging from tetrade-
cane (C14H30) to octatriacontane (C38H78), alcohols ranging from
tetradecanol (C14H30O) to octacosanol (C28H58O), fatty acids
ranging from tetradecanoic acid (C14H28O2) to octacosanoic acid
(C28H56O2)), or with lyophilized phenyl sepharose fractions, and
set to pH 7. In a separate series of experiments, highly pure S100B
dimer was supplemented with 90 mM imidazol at pH values
ranging from 4–9. Each sample was lyophilized and then dissolved
in H2O to obtain 20 mg/ml S100B and incubated for 24 h at 4 uC
and analysed by analytical gel filtration on a Superdex 200
column.
Analytical gel filtration
Analytical gel filtration chromatography was performed using a
Superdex200 column (Amersham Biosciences, Uppsala, Sweden)
connected to a BioLogic HR system (Biorad). The running buffer
was 25 mM sodium carbonate with 25 mM HCl, pH 7.3. The
column was calibrated with the following standards: ferritin
(440 kDa), Bovine serum albumin (67 kDa), ovalbumin (43 kDa),
calbindin D28k (30 kDa), carbonic anhydrase (30 kDa), a-
lactalbumin (14 kDa), calbindin D9k (8.5 kDa), the N-terminal
domain of calmodulin (8 kDa), and protein G B1 domain (6 kDa).
The elution time vs. log(Mw) was reasonably well fitted by a
straight line, R=0.93 (see supplementary information).
NMR spectroscopy
NMR spectra were obtained at 27 uC at 500 or 600 MHz on a
GE Omega 500 (rebuilt to a Varian/Bruker system) or Varian
Unity Plus 600 MHz spectrometer. Samples were dissolved in
D2O or CDCl3 and spectra recorded with solvent presaturation.
Between 64 and 20000 transients were accumulated depending on
the sample concentration.
Dynamic light scattering
Dynamic light scattering was performed using a ZetaSizer
Nano-S instrument from Malvern Instruments (Malvern Worcs,
UK). Fractions were collected directly from the Superdex200 gel
filtration column in 25 mM sodium carbonate with 25 mM HCl,
pH 7.3, and studied in single use plastic cuvettes to avoid
contamination by dust or other impurities.
Titration of p53 peptide with S100B
Binding parameters were obtained from titrations of p53
peptide with S100B dimer, tetramer or hexamer in 10 mM
BisTris buffer with 5 mM CaCl2 at pH 7.The peptide concentra-
tion was between 0.07 and 1.3 mM, and S100B aliquots were
added from a concentrated stock solutions. Fluorescence emission
at 330 nm (with excitation at 295 nm) was recorded on a Perkin
Elmer Luminescence Spectrometer LS50B connected to a Julabo
F25 thermostatic water bath set at 25 uC. Each titration point was
obtained by integration of the signal over 30 s after 1–1.5 minutes
of equilibration. The peptide concentration was determined using
absorbance spectroscopy and the S100B monomer concentration
in each stock solution was determined using amino acid analysis
after acid hydrolysis (analysis purchased from BMC, Uppsala). A
1:1 binding model was fitted to the fluorescence as a function of
total S100B monomer concentration using CaLigator software
[35]. Data at 0.07–0.9 mM p53 peptide were used to determine the
KD. The affinity as well as protein stock concentration were used
as variable parameters in the fits. In all cases (dimer, tetramer and
hexamer), there was a very good agreement between the fitted
protein concentration and that obtained from acid hydrolysis,
meaning that all species bind one p53 peptide per S100B
monomer. The reported binding constants are averages of at least
three independent measurements.
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